Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SMAD3 | P84022 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968975 | 0.88 | FTO (0.50) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL8215926 | 0.87 | FTO (0.49) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL79627 | 0.86 | HPGD (0.63) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL273427 | 0.86 | FTO (0.59) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL7525821 | 0.86 | FTO (0.48) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL6662140 | 0.86 | FTO (0.74) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL3189664 | 0.86 | FTO (0.66) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL7612094 | 0.86 | FTO (0.48) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL9474742 | 0.85 | FTO (0.58) | FTOMAPTHPGDMEN1HTT | |
| SCHEMBL3459139 | 0.85 | FTO (0.64) | FTOMAPTHPGDMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 420 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024158993-A1 | COMPOSITIONS, KITS, AND METHODS FOR DETECTING STI PATHOGEN SEQUENCES | Life Technologies Corporation (US) | 2024-08-02 | — | — | WO | claimed |
| US-20240254568-A1 | COMPOSITIONS, KITS, AND METHODS FOR DETECTING STI PATHOGEN SEQUENCES | Life Technologies Corporation | 2024-08-01 | — | — | US | claimed |
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. | 2023-08-17 | — | — | US | claimed |
| CN-116063472-A | anti-Spike S2 protein antibody and application thereof | 江苏东抗生物医药科技有限公司 | 2023-05-05 | — | — | CN | claimed |
| US-11560794-B2 | Solvent-stabilized colorimetric detection of amine-based additives | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-01-24 | — | — | US | claimed |
| US-11555787-B2 | Polymer-enhanced colorimetric detection of amine-based additives | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-01-17 | — | — | US | claimed |
| US-20220267416-A1 | HIV BINDING AGENTS | LAUSANNE UNIVERSITY HOSPITAL (CH) | 2022-08-25 | — | — | US | claimed |
| WO-2022162587-A1 | ANTI-SARS-COV-2 ANTIBODIES AND USE THEREOF IN THE TREATMENT OF SARS-COV-2 INFECTION | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.) (CH) | 2022-08-04 | — | — | WO | claimed |
| US-11401805-B2 | Colorimetric detection of amine-based shale inhibitors | HALLIBURTON ENERGY SERVICES, INC. (US) | 2022-08-02 | — | — | US | claimed |
| WO-2021251990-A1 | SOLVENT-STABILIZED COLORIMETRIC DETECTION OF AMINE-BASED ADDITIVES | HALLIBURTON ENERGY SERVICES, INC. (US) | 2021-12-16 | — | — | WO | claimed |
| CN-109553566-B | Anti-counterfeiting material with adjustable imaging waveband and preparation method and application thereof | 北京化工大学 | 2020-05-01 | — | — | CN | claimed |
| CN-109133074-A | Preparation method with the difunctional mesopore silicon dioxide nano material of fluorescence imaging and load medicine | 西北工业大学 | 2019-01-04 | — | — | CN | claimed |
| CN-107936607-A | A kind of preparation method of bromo fluoresceins cosmetic dyes | 上海染料研究所有限公司 | 2018-04-20 | — | — | CN | claimed |
| CN-103159772-A | Preparation and application of fluorescein lactam nitric oxide fluorescent probe | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2013-06-19 | — | — | CN | claimed |
| WO-2011046972-A2 | COMPOSITIONS AND METHODS FOR SUPPRESSING PRIMER INTERACTIONS | Life Technologies Corporation (US) | 2011-04-21 | — | — | WO | claimed |
| EP-1139982-A1 | PRODUCTION OF COLOURED IMPLANTS FOR PIGMENTING THE SKIN | Biotic Phocea (FR) | 2001-10-10 | — | — | EP | claimed |
| WO-2001026613-A1 | PRODUCTION OF COLOURED IMPLANTS FOR PIGMENTING THE SKIN | BIOTIC PHOCEA (FR) | 2001-04-19 | — | — | WO | claimed |
| EP-0568344-A1 | Fluoran compounds and process for their production | FUJI PHOTO FILM CO., LTD. (JP) | 1993-11-03 | — | — | EP | claimed |
| EP-0355390-A1 | Process for the adsorptive colouring of anodically obtained surfaces | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-02-28 | — | — | EP | claimed |
| US-4001027-A | FLUORESCEIN TYPE PIGMENT | BORDEN, INC. (US) | 1977-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | CHLSN, SLC47A1, CLSPN | FTO 3230/4885MAPT 2934/4885HPGD 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.